Revvity, Inc. (NYSE: RVTY)

Revvity is a leading provider of health science solutions technologies expertise and services that deliver complete workflows from discovery to development and diagnosis to cure. The company focuses on translational multi omics technologies biomarker identification imaging prediction screening detection diagnosis informatics and related areas. Headquartered in Waltham Massachusetts Revvity markets its products and services in more than 160 countries worldwide. As of December 28 2025 it employed approximately 11000 employees.

Revvity generates revenue through the sale of reagents instruments software and technology licensing offerings. Its product portfolio includes radiometric detection reagents microscopy imaging reagents homogeneous biochemical and cell based assay kits recombinant cell lines gene modulation tools immunoassay reagents and a broad array of antibodies. Instruments range from scintillation analyzers and high content imaging systems to automated liquid handling platforms ultrasound devices and cell counters. Software solutions cover high content imaging analysis data management electronic lab notebooks chemical drawing tools clinical trial platforms and AI enabled analytics. Technology and licensing revenues arise from proprietary platforms such as base editing systems expression platforms gene delivery services and preclinical service offerings. Customers include life science researchers pharmaceutical biotech and contract research organizations academic and government institutions as well as hospitals medical labs clinicians and diagnostic laboratories.

The company operates through the following segments: Life Sciences and Diagnostics.

• The Life Sciences segment provides a comprehensive portfolio that helps researchers understand disease mechanisms and develop treatments. It offers reagents such as radiometric detection chemicals microscopy imaging reagents homogeneous biochemical and cell based assay kits recombinant GPCR and ion channel cell lines gene modulation tools immunoassay reagents and antibodies. Instruments include scintillation analyzers high content imaging systems automated liquid handling platforms ultrasound systems and cell counters. Software includes high content imaging analysis data management electronic lab notebooks chemical drawing tools clinical trial platforms and AI enabled analytics. Technology and licensing cover base editing platforms expression systems gene delivery services and preclinical service offerings. The segment serves global pharmaceutical biotech contract research organizations academic and government institutions.

• The Diagnostics segment supplies instruments reagents assay platforms and software to hospitals medical labs clinicians and medical research professionals. Its focus areas include reproductive health immunodiagnostics and emerging market diagnostics. Products encompass prenatal and maternal health screening kits newborn screening metabolic disorder assays infectious disease testing platforms chemiluminescence immunoassays autoimmune testing tools and genomic workflow solutions based on PCR and next generation sequencing. The segment supports early detection of conditions such as Down syndrome hypothyroidism muscular dystrophy infertility and various metabolic disorders. It also provides products for oncology immunodiagnostics and drug discovery applications.

Revvity holds a strong position in the health science solutions market due to its broad integrated product portfolio global reach and sustained investment in research development and acquisitions. The company competes with a wide range of participants from large multinational corporations that offer diversified life sciences and diagnostics portfolios to specialized firms that concentrate on niche markets. Competitive advantages stem from its ability to deliver end to end workflow solutions its technological innovation in areas such as multi omics imaging and AI enhanced analytics and its extensive sales and service presence in over 160 countries. The firm also benefits from a diversified customer base that reduces reliance on any single market segment and from a disciplined approach to capital allocation that supports organic growth strategic acquisitions and shareholder returns.

Revvity serves a diverse customer base that includes life science researchers at pharmaceutical biotech and contract research organizations academic and government institutions hospitals medical labs clinicians diagnostic laboratories expectant mothers and newborn screening programs. Specific customer names are not disclosed in the filing but the company reports that its products are used in more than 160 countries across a variety of end markets.